AZD5363
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
AZD5363是一种新型有效的磷酸肌醇-3-激酶(PI3K)/ Akt信号通路抑制剂,IC50值约为200 nM[1]。
AZD5363抑制阉割性前列腺癌(CRPC)的发展。AZD5363诱导簇集蛋白(CLU)和自噬,可能作为细胞保护反应,可以影响PI3K/Akt下游信号[2]。AZD5363以剂量依赖的方式抑制许多人类肿瘤细胞的生长,该作用方式可以是单一疗法,也可以与HER2的抑制剂联合用于乳腺癌模型中[3]。切割PARP的表达及caspase 3的活性检测表明,AZD5363诱导细胞凋亡[1]。
最重要的是,AZD5363在体内显著靶向PI3K/Akt信号通路,从而减少血清PSA水平和肿瘤体积,最终,AZD5363可能推迟CRPC的发展[1]。
参考文献:
[1] Thomas C, Crafter C, Davies B, Zoubeidi A, Gleave ME. AZD5363, A novel AKT inhibitor, delays prostate cancer progression. The Journal of Urology. May 2011. 185(4S): e292-293.
[2] Kumano M, Zhang F, Shiota M, Crafter C, Davies B, Zoubeidi A, Gleave M. Clusterin knockdown enhances antitumor activity of a novel Akt inhibitor, AZD5363, through inhibition of autophagy in prostate cancer. The Journal of Urology. May 21 2012. e392.
[3] Davies BR, Greenwood H, Dudley P, et al. Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background. Mol. Cancer Ther. Arp 2012. 11: 873.
- 1.Wang C, Bai F, et al. "Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression." Breast Cancer Res. 2018 Jul 11;20(1):74. PMID:29996906
- 2.Du Q, Zhang S, et al. "Astragaloside IV Inhibits Adipose Lipolysis and Reduces Hepatic Glucose Production via Akt Dependent PDE3B Expression in HFD-Fed Mice." Front Physiol. 2018 Jan 23;9:15. PMID:29410630
- 3.Peng T, Dou QP. "Everolimus Inhibits Growth of Gemcitabine-Resistant Pancreatic Cancer Cells via Induction of Caspase-Dependent Apoptosis and G(2) /M Arrest." J Cell Biochem. 2017 Feb 6. PMID:28165150
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 428.92 |
Cas No. | 1143532-39-1 |
Formula | C21H25ClN6O2 |
Solubility | ≥21.45 mg/mL in DMSO; insoluble in H2O; ≥5.04 mg/mL in EtOH with ultrasonic |
Chemical Name | 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide |
SDF | Download SDF |
Canonical SMILES | C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4 |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
细胞实验[1] : | |
细胞系 |
BT474c(Her2? PIK3CA突变乳腺),LNCaP(PTEN-nul前列腺)和MDA-MB-468(PTEN-nul乳腺)癌细胞中的GSK3 |
溶解方法 |
该化合物在DMSO中的溶解度大于10mM。若配制更高浓度的溶液,一般步骤如下:请将试管置于37℃加热10分钟和/或将其置于超声波浴中震荡一段时间。原液于-20℃可放置数月。 |
反应条件 |
pGSK3β(IC50:BT474c中为0.76μM,LNCaP中为0.06μM,MDA-MB-468中为0.38μM)pPRAS40(IC50:BT474c中为0.31μM,LNCaP中为0.22μM,MDA-MB-468中为0.39μM)pFOXO3a染色体易位(IC50:BT474c中为0.69μM) |
实验结果 |
AZD5363抑制AKT底物的磷酸化,在3个细胞系中的IC50值为0.06至0.76μM。AZD5363还有效抑制BT474c细胞和LNCaP细胞中S6和4E-BP1的磷酸化。 |
动物实验[1] : | |
动物模型 |
BT474c肿瘤异种移植裸鼠 |
剂量 |
溶于DMSO/Kleptose缓冲液,口服给药300或100mg/kg急性剂量的AZD5363。 |
实验结果 |
裸鼠中,口服给药AZD5363以剂量和时间依赖性的方式减少PRAS40、GSK3和S6的磷酸化。给予300mg/kg剂量的AZD 5363后显著抑制3种生物标志物的磷酸化,抑制效果的持续时间至少24小时。100mg/kg剂量的AZD5363显著抑制3种生物标志物的磷酸化,抑制效果的持续时间至少8小时。 |
注意事项 |
请测试所有化合物在室内的溶解度,实际溶解度和理论值可能略有不同。这是由实验系统的误差引起的,属于正常现象。 |
References: [1] Davies B R, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Molecular cancer therapeutics, 2012, 11(4): 873-887. |
描述 | AZD5363是吡咯并嘧啶衍生的Akt抑制剂,IC50值小于10 nM。 | |||||
靶点 | Akt | |||||
IC50 | <10 nM |
质量控制和MSDS
- 批次: